2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Motor Activity
4
Prostatic Neoplasms
3
Malnutrition
3
Stomach Neoplasms
2
Neoplasms
2
Frailty
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urologic Neoplasms
1
Smoking
1
Sezary Syndrome
1
Sarcoma, Kaposi
1
Sarcoma
1
Risk Reduction Behavior
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Patient Preference
1
Pain
1
Ovarian Neoplasms
1
Osteosarcoma
1
Obesity
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Cisplatin
116
Radiotherapy
84
Paclitaxel
77
Fluorouracil
62
Carboplatin
41
Drug Therapy
38
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
Neoadjuvant Therapy
24
Oxaliplatin
23
toripalimab
22
sintilimab
19
camrelizumab
19
Radiation
19
Esophagectomy
18
Capecitabine
17
130-nm albumin-bound paclitaxel
17
Surgical Procedures, Operative
16
Nivolumab
16
Leucovorin
15
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
Immune Checkpoint Inhibitors
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Nutritional Support
×
Clear all
NCT01248299
2019-05-16
E-DIS
Centre Oscar Lambret
Phase 2
Terminated
105 enrolled